β-Cyclodextrin as a Functional Excipient Used for Enhancing the Diminazene Aceturate Bioavailability
Authors:
- Narcisa MarangociNMNarcisa Marangoci
- Daniel TimpuDTDaniel Timpu
- Andreia CorciovaACAndreia Corciova
- Cornelia MirceaCMCornelia Mircea
- Anca-Roxana PetroviciAnca-Roxana Petrovici
- Alina NicolescuANAlina Nicolescu
- Elena-Laura UrsuElena-Laura Ursu
- Valentin NastasaVNValentin Nastasa
- Andra-Cristina BostanaruABAndra-Cristina Bostanaru
- Mihai MaresMihai Mares
- Mihaela PerteaMPMihaela Pertea
- Mariana PintealaMariana Pinteala
Open Access
- 22 June 2019
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (6) , 295
Abstract
In this study, we proposed formulations of diminazene aceturate (DA) designed to improve its bioavailability and to maximize the therapeutic index in animals by overcoming the rapid degradation under the acidic pH of the stomach. An important consequence is the fact that its amount in the bloodstream is close to the administered dose. This was made possible by incorporating DA into the β-cyclodextrin’s (βCD) cavity in a molar ratio of 1:1. The structure of the resulted inclusion complex was established by Raman, DSC, and Wide-Angle X ray Diffraction (WAXD) in solid state and by 1H-NMR and H-H ROESY in aqueous solutions. The stoichiometry of the DA:βCD inclusion complex was obtained by using the continuous variation method (Job’s plot), considering the chemical shifts variations of protons from both DA and βCD compounds in 1H-NMR spectra. The biological activity was estimated in vitro by antioxidant activity and in vivo by comparing the bioavailability of parent DA and its inclusion complexes after a single dose administration in Wistar rats by using the HPLC method on their blood plasma. In vitro tests showed an improved antioxidant activity. In vivo tests have shown that the DA concentration is always much higher in blood plasma of rats when DA:βCD inclusion complex of 1:1 molar ratio was administered (i.e., at 60 min, DA is around 11 and 3 times higher when DA:βCD inclusion complex of 1:1 molar ratio was administered than the parent DA one and DA:βCD lyophilized mixture of 1:2 molar ratio, respectively).Keywords
Funding Information
- Ministery of Research and Innovation, CNCS - UEFISCDI (PN-III-P4-ID-PCCF-2016-0050, within PNCDI III)
This publication has 33 references indexed in Scilit:
- Inclusion complex of a new propiconazole derivative with β-cyclodextrin: NMR, ESI–MS and preliminary pharmacological studiesResults in Pharma Sciences, 2011
- Cyclodextrin-based inclusion complexation bridging supramolecular chemistry and macromolecular self-assemblyChemical Society Reviews, 2011
- Cyclodextrins in delivery systems: ApplicationsJournal of Pharmacy and Bioallied Sciences, 2010
- Vibrational properties of ibuprofen–cyclodextrin inclusion complexes investigated by Raman scattering and numerical simulationJournal of Raman Spectroscopy, 2008
- Inclusion complexes of 5-flucytosine with β-cyclodextrin and hydroxypropyl-β-cyclodextrin: characterization in aqueous solution and in solid stateJournal of Inclusion Phenomena and Macrocyclic Chemistry, 2008
- Methyl-β-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: Involvement of Akt, NF-κB and Bcl-2Toxicology and Applied Pharmacology, 2006
- Degradation of berenil (diminazene aceturate) in acidic aqueous solutionJournal of Pharmacy and Pharmacology, 2004
- A Raman spectroscopic study of the diclofenac sodium–β-cyclodextrin interactionEuropean Journal of Pharmaceutical Sciences, 2004
- Determination of Association Constants (Ka) from Solution NMR DataTetrahedron, 2000
- N=N Vibrational Frequencies and Fragmentation Patterns of Substituted 1-Aryl-3,3-Dialkyl-Triazenes: Comparison with other High-Nitrogen CompoundsApplied Spectroscopy, 1993